Arbutus Biopharma (ABUS) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 0.79.
- Arbutus Biopharma's Equity Ratio rose 407.66% to 0.79 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.79, marking a year-over-year increase of 407.66%. This contributed to the annual value of 0.74 for FY2024, which is 69.06% up from last year.
- Arbutus Biopharma's Equity Ratio amounted to 0.79 in Q3 2025, which was up 407.66% from 0.8 recorded in Q2 2025.
- Arbutus Biopharma's Equity Ratio's 5-year high stood at 0.83 during Q4 2021, with a 5-year trough of 0.68 in Q1 2025.
- Over the past 5 years, Arbutus Biopharma's median Equity Ratio value was 0.75 (recorded in 2023), while the average stood at 0.75.
- Per our database at Business Quant, Arbutus Biopharma's Equity Ratio soared by 1139.63% in 2021 and then tumbled by 1548.53% in 2022.
- Arbutus Biopharma's Equity Ratio (Quarter) stood at 0.83 in 2021, then dropped by 15.49% to 0.7 in 2022, then grew by 4.84% to 0.73 in 2023, then increased by 0.69% to 0.74 in 2024, then rose by 7.15% to 0.79 in 2025.
- Its Equity Ratio stands at 0.79 for Q3 2025, versus 0.8 for Q2 2025 and 0.68 for Q1 2025.